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linical Classification
f Pulmonary Hypertension
read with interest the recently published Dana Point clinical
lassification of pulmonary arterial hypertension (PAH) in the
ournal supplement (1). Any globally relevant scheme of clinical
lassification cannot and should not lose sight of the prevalence of
he disease state worldwide. Although the classification is not
ased on prevalence, and causes such as left ventricular systolic and
iastolic dysfunction, in which PAH is not of primary importance,
re kept in group 2 only, downgrading PAH associated with
ongenital heart disease (CHD) in their classification scheme to
.4.4 seems unjustified. Although precise epidemiological data are
ot available for most causes of PAH, it is easy to understand the
mportance of PAH due to CHD on a global scale. In 2009, nearly
0% of the world’s population lives in the less and least developed
egions of the world. These regions also have a younger population
rofile, higher growth rates despite high infant mortality, and poor
acilities for the management of CHD. Because the incidence of
HD is more or less uniform at 6 to 8 per 1,000 live births, these
ata easily would translate into a very high burden of PAH
ssociated with CHD in the world, more than any cause listed in
roup 1.4. Most patients with CHD in the Western world
ndergo surgery early in life, and therefore this facet of CHD is
ess and less evident there, but the various aspects of the patho-
enesis of PAH associated with CHD are also far from resolved.
n view of the continued epidemiological, scientific, and pedagog-
cal importance, PAH associated with CHD should be classified as
.4.1 or even higher.
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eply
he relevance of congenital heart disease (CHD) in the setting of
ulmonary arterial hypertension (PAH) is unquestionable, as
tated in the letter by Dr. Kothari. However, it is important to
mphasize that the core structure of the updated clinical classifi-
ation of pulmonary hypertension (1) is not based on the relevance
f the topic or on the prevalence of the disease; thus, there is no
ierarchical level within each one of the groups. The fact that
chistosomiasis-associated PAH is classified as item 1.4.5 does not
ake it more or less important than human immunodeficiency
irus infection–associated PAH, classified as item 1.4.2. The same
an be directly extrapolated to the other 4 groups. Consequently,
ne could not consider that CHD-associated PAH has been
owngraded from the previous classification. This classification has
ven strengthened the role of CHD by describing not only the
natomic-pathophysiologic classification of congenital systemic-
o-pulmonary shunts associated with PAH (see Table 4 in the
lassification [1]) but also the clinical classification of congenital
ystemic-to-pulmonary shunts associated with PAH (see Table 5
n the classification [1]) to disseminate the current knowledge on
he management of such relevant conditions.
The prevalence of the different forms of pulmonary hyperten-
ion is extremely important for the appropriate understanding of
he whole pulmonary hypertension scenario, mainly considering
hat regional characteristics, such as local altitude, sanitary condi-
ions, and health care infrastructure and organization, may play a
ignificant role (2). Even considering that this is not related to the
rder in the updated classification, the commentary from Dr.
othari should be considered as a reinforcement of the need for
obust registries of the different forms of pulmonary hypertension
3) to serve as a basis for international collaborative efforts in the
ulmonary hypertension field.
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